1.Incidence and case fatality of stroke in Korea, 2011-2020
Jenny MOON ; Yeeun SEO ; Hyeok-Hee LEE ; Hokyou LEE ; Fumie KANEKO ; Sojung SHIN ; Eunji KIM ; Kyu Sun YUM ; Young Dae KIM ; Jang-Hyun BAEK ; Hyeon Chang KIM
Epidemiology and Health 2024;46(1):e2024003-
OBJECTIVES:
Stroke remains the second leading cause of death in Korea. This study was designed to estimate the crude, age-adjusted and age-specific incidence rates, as well as the case fatality rate of stroke, in Korea from 2011 to 2020.
METHODS:
We utilized data from the National Health Insurance Services from January 1, 2002 to December 31, 2020, to calculate incidence rates and 30-day and 1-year case fatality rates of stroke. Additionally, we determined sex and age-specific incidence rates and computed age-standardized incidence rates by direct standardization to the 2005 population.
RESULTS:
The crude incidence rate of stroke hovered around 200 (per 100,000 person-years) from 2011 to 2015, then surged to 218.4 in 2019, before marginally declining to 208.0 in 2020. Conversely, the age-standardized incidence rate consistently decreased by 25% between 2011 and 2020. When stratified by sex, the crude incidence rate increased between 2011 and 2019 for both sexes, followed by a decrease in 2020. Age-standardized incidence rates displayed a downward trend throughout the study period for both sexes. Across all age groups, the 30-day and 1-year case fatality rates of stroke consistently decreased from 2011 to 2019, only to increase in 2020.
CONCLUSIONS
Despite a decrease in the age-standardized incidence rate, the total number of stroke events in Korea continues to rise due to the rapidly aging population. Moreover, 2020 witnessed a decrease in incidence but an increase in case fatality rates.
2.Metabolic Syndrome Severity Score for Predicting Cardiovascular Events: A Nationwide Population-Based Study from Korea
Yo Nam JANG ; Jun Hyeok LEE ; Jin Sil MOON ; Dae Ryong KANG ; Seong Yong PARK ; Jerim CHO ; Jang-Young KIM ; Ji Hye HUH
Diabetes & Metabolism Journal 2021;45(4):569-577
Background:
Recently, a metabolic syndrome severity score (MS score) using a dataset of the Korea National Health and Nutrition Examination Surveys has been developed. We aimed to determine whether the newly developed score is a significant predictor of cardiovascular (CV) events among the Korean population.
Methods:
From the Korean National Health Insurance System, 2,541,364 (aged 40 to 59 years) subjects with no history of CV events (ischemic stroke or myocardial infarction [MI]), who underwent health examinations from 2009 to 2011 and were followed up until 2014 to 2017, were identified. Cox proportional hazard model was employed to investigate the association between MS score and CV events. Model performance of MS score for predicting CV events was compared to that of conventional metabolic syndrome diagnostic criteria (Adult Treatment Program III [ATP-III]) using the Akaike information criterion and the area under the receiver operating characteristic curve.
Results:
Over a median follow-up of 6 years, 15,762 cases of CV events were reported. MS score at baseline showed a linear association with incident CV events. In the multivariable-adjusted model, the hazard ratios (95% confidence intervals) comparing the highest versus lowest quartiles of MS score were 1.48 (1.36 to 1.60) for MI and 1.89 (1.74 to 2.05) for stroke. Model fitness and performance of the MS score in predicting CV events were superior to those of ATP-III.
Conclusion
The newly developed age- and sex-specific continuous MS score for the Korean population is an independent predictor of ischemic stroke and MI in Korean middle-aged adults even after adjusting for confounding factors.
3.Metabolic Syndrome Severity Score for Predicting Cardiovascular Events: A Nationwide Population-Based Study from Korea
Yo Nam JANG ; Jun Hyeok LEE ; Jin Sil MOON ; Dae Ryong KANG ; Seong Yong PARK ; Jerim CHO ; Jang-Young KIM ; Ji Hye HUH
Diabetes & Metabolism Journal 2021;45(4):569-577
Background:
Recently, a metabolic syndrome severity score (MS score) using a dataset of the Korea National Health and Nutrition Examination Surveys has been developed. We aimed to determine whether the newly developed score is a significant predictor of cardiovascular (CV) events among the Korean population.
Methods:
From the Korean National Health Insurance System, 2,541,364 (aged 40 to 59 years) subjects with no history of CV events (ischemic stroke or myocardial infarction [MI]), who underwent health examinations from 2009 to 2011 and were followed up until 2014 to 2017, were identified. Cox proportional hazard model was employed to investigate the association between MS score and CV events. Model performance of MS score for predicting CV events was compared to that of conventional metabolic syndrome diagnostic criteria (Adult Treatment Program III [ATP-III]) using the Akaike information criterion and the area under the receiver operating characteristic curve.
Results:
Over a median follow-up of 6 years, 15,762 cases of CV events were reported. MS score at baseline showed a linear association with incident CV events. In the multivariable-adjusted model, the hazard ratios (95% confidence intervals) comparing the highest versus lowest quartiles of MS score were 1.48 (1.36 to 1.60) for MI and 1.89 (1.74 to 2.05) for stroke. Model fitness and performance of the MS score in predicting CV events were superior to those of ATP-III.
Conclusion
The newly developed age- and sex-specific continuous MS score for the Korean population is an independent predictor of ischemic stroke and MI in Korean middle-aged adults even after adjusting for confounding factors.
4.Metabolic Syndrome Severity Score in Korean Adults: Analysis of the 2010–2015 Korea National Health and Nutrition Examination Survey
Ji Hye HUH ; Jun Hyeok LEE ; Jin Sil MOON ; Ki Chul SUNG ; Jang Young KIM ; Dae Ryong KANG
Journal of Korean Medical Science 2019;34(6):e48-
BACKGROUND: Continuous metabolic syndrome (MS) severity scores that can track metabolic risk in individuals over time have been developed for Western populations. The present study aimed to develop gender- and age-specific equations for MS severity scores in Korean adults. METHODS: Using data from the Korea National Health and Nutrition Examination Surveys (KNHANES) IV (2010–2012) and VI (2013–2015), we performed a confirmatory factor analysis of single MS factor that allowed for differential loadings across groups to generate gender- and age-specific, continuous MS severity scores. Then, we validated this equation in a different dataset of Korean adults. RESULTS: In confirmatory analysis, waist circumference had the highest factor loading, indicating that waist circumference had the strongest correlation with MS among Korean adults. Lower factor loadings (< 0.4) among Korean adults aged 40–59 years were noted for systolic blood pressure and fasting glucose. MS severity score values were significantly correlated with metabolic parameters, including high-sensitivity C-reactive-protein, glycated hemoglobin, and homeostasis model assessment of insulin resistance. Furthermore, MS severity scores well predicted traditional MS according to receiver operating characteristic analysis in a validation dataset (KNHANES VII). In a longitudinal cohort dataset, participants diagnosed with Adult Treatment Program III (ATP-III) MS after an initial assessment had progressively higher baseline MS severity scores in relationship to their time until ATP-III MS diagnosis. CONCLUSION: The new MS severity score equations for Korean adults proposed in this study provide a clinically-accessible continuous measure of MS for potential use in identifying adults at higher risk for MS-related diseases and following changes within individuals over time.
Adult
;
Blood Pressure
;
Cohort Studies
;
Dataset
;
Diagnosis
;
Epidemiology
;
Fasting
;
Glucose
;
Hemoglobin A, Glycosylated
;
Homeostasis
;
Humans
;
Insulin Resistance
;
Korea
;
Nutrition Surveys
;
Obesity
;
ROC Curve
;
Waist Circumference
5.Revision and update on clinical practice guideline for liver cirrhosis.
Ki Tae SUK ; Soon Koo BAIK ; Jung Hwan YOON ; Jae Youn CHEONG ; Yong Han PAIK ; Chang Hyeong LEE ; Young Seok KIM ; Jin Woo LEE ; Dong Joon KIM ; Sung Won CHO ; Seong Gyu HWANG ; Joo Hyun SOHN ; Moon Young KIM ; Young Bae KIM ; Jae Geun KIM ; Yong Kyun CHO ; Moon Seok CHOI ; Hyung Joon KIM ; Hyun Woong LEE ; Seung Up KIM ; Ja Kyung KIM ; Jin Young CHOI ; Dae Won JUN ; Won Young TAK ; Byung Seok LEE ; Byoung Kuk JANG ; Woo Jin CHUNG ; Hong Soo KIM ; Jae Young JANG ; Soung Won JEONG ; Sang Gyune KIM ; Oh Sang KWON ; Young Kul JUNG ; Won Hyeok CHOE ; June Sung LEE ; In Hee KIM ; Jae Jun SHIM ; Gab Jin CHEON ; Si Hyun BAE ; Yeon Seok SEO ; Dae Hee CHOI ; Se Jin JANG
The Korean Journal of Hepatology 2012;18(1):1-21
No abstract available.
Antiviral Agents/therapeutic use
;
Ascites/diagnosis/prevention & control/therapy
;
Cholagogues and Choleretics/therapeutic use
;
Fatty Liver/diagnosis/diet therapy
;
Fatty Liver, Alcoholic/diagnosis/drug therapy
;
Hemorrhage/prevention & control/therapy
;
Hepatic Encephalopathy/diagnosis/prevention & control/therapy
;
Hepatitis B, Chronic/diagnosis/drug therapy
;
Hepatitis C, Chronic/diagnosis/drug therapy
;
Humans
;
Liver Cirrhosis/*diagnosis/drug therapy/pathology/*therapy
;
Liver Cirrhosis, Biliary/drug therapy
;
Vasodilator Agents/therapeutic use
6.Outcomes after bleomycin, etoposide and cisplatin combination chemotherapy in patients with ovarian yolk sac tumor.
Ji Young KIM ; Yu Jung SHIN ; Jei Won MOON ; Jeong Yeol PARK ; Dae Yeon KIM ; Joo Hak LEE ; Jong Hyeok KIM ; Yong Man KIM ; Young Tak KIM ; Joo Hyun NAM
Korean Journal of Obstetrics and Gynecology 2010;53(11):1007-1013
OBJECTIVE: The aim of this study was to evaluate the oncologic and reproductive outcomes of patients with ovarian yolk sac tumor after bleomycin, etoposide, cisplatin (BEP) chemotherapy following surgery. METHODS: Of 145 patients with histologically confirmed malignant ovarian germ cell tumor, 43 had yolk sac tumor and received BEP chemotherapy after surgery. A retrospective analysis of these patients was performed. RESULTS: The mean age of 43 patients was 24.8 years (range, 7 to 59 years). Thirty eight patients were nulliparous. Of 179 BEP chemotherapy cycles, grade 1~2 hematologic and non-hematologic adverse events occurred in 46 cycles in 21 patients. Thirty nine patients showed complete remission, 1 patient showed partial remission, and 3 patient had progressive disease during BEP chemotherapy. After median follow-up time of 57 months (range, 3 to 153 months), 5 patients had recurrent disease and three of them died of disease. The 5-year recurrence free survival rate and overall survival rate were 86% and 94%, respectively. After chemotherapy, all but one premenarchal patients had normal menstruation. Of them 5 patients tried to conceive and 3 of them succeeded in pregnancy. CONCLUSION: BEP chemotherapy was very safe and effective in patients with ovarian yolk sac tumor. Survival outcomes are excellent and reproductive outcomes are promising after BEP chemotherapy.
Bleomycin
;
Cisplatin
;
Drug Therapy, Combination
;
Endodermal Sinus Tumor
;
Etoposide
;
Female
;
Follow-Up Studies
;
Humans
;
Menstruation
;
Neoplasms, Germ Cell and Embryonal
;
Pregnancy
;
Recurrence
;
Retrospective Studies
;
Survival Rate
;
Yolk Sac
7.Idiopathic Retroperitoneal Fibrosis Associated with Hashimoto's Thyroiditis in an Old-aged Man.
Jung Eun LEE ; Seung Hyeok HAN ; Dong Ki KIM ; Sung Jin MOON ; Kyu Hun CHOI ; Ho Yung LEE ; Dae Suk HAN ; Nam Hoon CHO ; Young Taik OH ; Beom Seok KIM
Yonsei Medical Journal 2008;49(6):1032-1035
Idiopathic retroperitoneal fibrosis (IRPF) is a rare disease characterized by a retroperitoneal inflammatory proliferative fibrosing process. Hashimoto's thyroiditis is the most common inflammatory condition of the thyroid gland; and is a frequently-occurring autoimmune disorder manifesting predominantly in middle-aged women. We report a rare association of IRPF with Hashimoto's thyroiditis in a 67-year-old man demonstrating good response to steroid therapy.
Aged
;
Anti-Inflammatory Agents/therapeutic use
;
Hashimoto Disease/*complications/drug therapy
;
Humans
;
Male
;
Pregnenediones/therapeutic use
;
Retroperitoneal Fibrosis/*complications/drug therapy/pathology
8.A comparison study between mycophenolate mofetil and cyclophosphamide for treatment of proliferative lupus nephritis.
Sung Jin MOON ; Dong Ki KIM ; Sun Young PARK ; Jae Hyun CHANG ; Hyun Wook KIM ; Jung Eun LEE ; Seung Hyeok HAN ; Kwang Il KO ; Dong Hyun KIM ; Chan Ho KIM ; Sang Won LEE ; Beom Suk KIM ; Shin Wook KANG ; Dae Suk HAN ; Ho Yung LEE ; Yong Beom PARK ; Soo Kon LEE ; Kyu Hun CHOI
Korean Journal of Medicine 2008;74(6):640-647
BACKGROUND/AIMS: Our study aimed to evaluate the efficacy of MMF as compared with intravenous cyclophosphamide as induction therapy for proliferative lupus nephritis in Koreans. METHODS: Forty-three patients who were diagnosed with proliferative lupus nephritis (WHO Class III and IV) between Jan 2000 and Dec 2006 were included in this study. Nineteen patients were treated with oral MMF (initial dose: 1.0 g/day and then it was increased to 2.0 g/day) and 24 patients were treated with 0.75-1.0 g/m2 of monthly intravenous cyclophosphamide (CP) followed by subsequent treatment with oral corticosteroid (initial dose 1 mg/kg/day and then it was slowly tapered down) for 6 months. The demographic and laboratory findings, the response rate and the adverse events were reviewed retrospectively and these were compared between the two groups. RESULTS: A complete response occurred in 7 out of the 19 patients (36.8%) treated with MMF and in 8 out of the 24 patients (33.3%) treated with CP, and the difference was not significantly different between the two groups (p=0.66). A partial response was achieved in 52.6% and 45.8%, respectively. There were no significant differences of the laboratory findings such as serum albumin, C3, C4, the urine protein/creatinine ratio and serum creatinine after treatment for 6 months. In addition, both groups had similar rates of adverse events. CONCLUSIONS: Our study showed that for the treatment of lupus nephritis, MMF was as effective as IV cyclophosphamide with similar adverse events. This finding suggests that MMF could be an alternative treatment for active lupus nephritis as induction therapy.
Creatinine
;
Cyclophosphamide
;
Humans
;
Lupus Nephritis
;
Mycophenolic Acid
;
Retrospective Studies
;
Serum Albumin
9.Factors associated with Hypokalemia in Continuous Ambulatory Peritoneal Dialysis Patients.
Hyun Wook KIM ; Jae Hyun CHANG ; Sun Young PARK ; Sung Jin MOON ; Dong Ki KIM ; Jung Eun LEE ; Seung Hyeok HAN ; Beum Seok KIM ; Shin Wook KANG ; Kyu Hun CHOI ; Ho Young LEE ; Dae Suk HAN
Electrolytes & Blood Pressure 2007;5(2):102-110
Hypokalemia is a frequent problem in patients on continuous ambulatory peritoneal dialysis (CAPD) and is affected by multiple factors. To evaluate factors associated with hypokalemia, we studied 68 patients on maintenance CAPD treatment for at least six months. In univariate analysis, patients with hypokalemia were associated with older age and the presence of diabetes mellitus. Serum albumin, calcium-phosphate product, triglyceride, body mass index, protein nitrogen appearance, and lean body mass assessed by creatinine kinetics were significantly lower as compared to those without hypokalemia. Serum C-reactive protein was significantly higher in the patients with hypokalemia. Multivariate stepwise linear regression analysis revealed that the serum albumin level and the ultrafiltration volume at the peritoneal equilibration test were independent factors associated with hypokalemia. This suggests that the serum potassium level may be an important nutritional marker in CAPD patients. Further longitudinal investigation is needed to clarify this relationship.
Body Mass Index
;
C-Reactive Protein
;
Creatinine
;
Diabetes Mellitus
;
Humans
;
Hypokalemia*
;
Kinetics
;
Linear Models
;
Nitrogen
;
Nutritional Status
;
Peritoneal Dialysis, Continuous Ambulatory*
;
Potassium
;
Serum Albumin
;
Triglycerides
;
Ultrafiltration
10.Differences in Pathologic Findings and Gene Expressions of Renal Tissue according to Steroid Responsiveness in Adult-Onset Minimal Change Disease.
Sun Young PARK ; Seung Hyeok HAN ; Hyung Jung OH ; Seung Jun KIM ; Dong Eun YOO ; Han Sung LEE ; Tae Hee LEE ; Sung Jin MOON ; Hoon Young CHOI ; Dae Suk HAN ; Shin Wook KANG
Korean Journal of Nephrology 2007;26(1):52-60
PURPOSE: Compared to children, adult MCD patients tend to have a slower response to steroids, however, little is known about the relationships between pathologic findings or the expression of certain gene and the response to steroid treatment in adult-onset MCD. This study was undertaken to investigate the differences in pathologic findings and the mRNA expression of nephrin and glucocorticoid receptor (GCR) in renal tissue according to steroid responsiveness in adult-onset MCD. METHODS: Twenty-eight adult patients who presented with idiopathic nephrotic syndrome at our institution and fulfilled the criteria for MCD clinically and pathologically were chosen for this study. Based on the response to steroid treatment, patients were divided into two groups: early responders (ER) in whom CR was achieved within 4 weeks of steroid treatment; late responders (LR) in whom CR was achieved after 4 weeks of steroid treatment. RESULTS: Of the 28 patients, ER consisted of 20 patients. Time to CR was significantly shorter in ER compared to LR (16.5+/-0.9 vs. 52.0+/-4.9 days, p<0.01). The proportion of patients with minimal IgM deposition on immunofluorescence was significantly higher in LR compared to ER (75.0% vs. 30.0%, p<0.01). On the other hands, the mRNA expression of GCR, assessed by real time-PCR, was significantly lower in LR than that in ER (p<0.005), whereas nephrin mRNA expression was not different between the two groups. CONCLUSION: The presence of glomerular IgM deposition and the amount of GCR in renal tissue may be useful predictors of steroid responsiveness in adult MCD patients.
Adult
;
Adult Children
;
Fluorescent Antibody Technique
;
Gene Expression*
;
Hand
;
Humans
;
Immunoglobulin M
;
Nephrosis, Lipoid*
;
Nephrotic Syndrome
;
Receptors, Glucocorticoid
;
RNA, Messenger
;
Steroids

Result Analysis
Print
Save
E-mail